Cargando…
Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an overall 5-year survival rate of 9.3%, and this malignancy is expected to become the second leading cause of cancer-related death by 2030. Gemcitabine resistance develops within weeks of PDAC patient’s chemo...
Autores principales: | Chen, Ya-Hui, Chen, Yi-Chun, Lin, Chi-Chen, Hsieh, Yao-Peng, Hsu, Chien-Sheng, Hsieh, Ming-Chia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306478/ https://www.ncbi.nlm.nih.gov/pubmed/32606957 http://dx.doi.org/10.2147/CMAR.S247876 |
Ejemplares similares
-
AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2
por: Fahy, B N, et al.
Publicado: (2003) -
Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells
por: DUONG, HONG-QUAN, et al.
Publicado: (2014) -
Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells
por: DUONG, HONG-QUAN, et al.
Publicado: (2012) -
Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2
pancreatic cell lines
por: Park, S.H., et al.
Publicado: (2014) -
Effects of a Non Thermal Plasma Treatment Alone or in Combination with Gemcitabine in a MIA PaCa2-luc Orthotopic Pancreatic Carcinoma Model
por: Brullé, Laura, et al.
Publicado: (2012)